Sanofi $SNY Shares Sold by London & Capital Asset Management Ltd

London & Capital Asset Management Ltd decreased its holdings in Sanofi (NASDAQ:SNY) by 69.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 80,955 shares of the company’s stock after selling 187,997 shares during the quarter. London & Capital Asset Management Ltd’s holdings in Sanofi were worth $3,911,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in SNY. Callodine Capital Management LP increased its holdings in shares of Sanofi by 26.9% in the 2nd quarter. Callodine Capital Management LP now owns 515,209 shares of the company’s stock valued at $24,890,000 after purchasing an additional 109,240 shares in the last quarter. Financial & Tax Architects LLC increased its holdings in Sanofi by 3.1% in the second quarter. Financial & Tax Architects LLC now owns 12,940 shares of the company’s stock valued at $625,000 after buying an additional 390 shares in the last quarter. Brown Advisory Inc. increased its holdings in Sanofi by 34.1% in the second quarter. Brown Advisory Inc. now owns 421,960 shares of the company’s stock valued at $20,385,000 after buying an additional 107,324 shares in the last quarter. GeoWealth Management LLC lifted its position in shares of Sanofi by 14.7% during the 2nd quarter. GeoWealth Management LLC now owns 21,159 shares of the company’s stock valued at $1,022,000 after acquiring an additional 2,704 shares during the period. Finally, First Trust Advisors LP boosted its stake in shares of Sanofi by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 869,201 shares of the company’s stock worth $41,991,000 after acquiring an additional 112,091 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

NASDAQ SNY opened at $48.44 on Tuesday. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The business has a fifty day moving average of $49.95 and a 200-day moving average of $49.13. The stock has a market cap of $118.94 billion, a price-to-earnings ratio of 11.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.44.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 24th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the business posted $2.25 EPS. The firm’s quarterly revenue was down 7.5% compared to the same quarter last year. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SNY. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Sanofi in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.